Morais Research Group
Medicinal Inorganic Chemistry Lab
Medicinal Inorganic Chemistry Lab
Tânia S. Morais, Ph.D.
Assistant Research
Centro de Química Estrutural | Institute of Molecular Sciences (CQE-IMS)
Department of Chemistry and Biochemistry
Faculty of Sciences, University of Lisbon
Campo Grande, 1749-016 Lisbon, Portugal
Direct Phone: +351 217 500 954
Email: tsmorais@ciencias.ulisboa.pt
Tânia Morais is an Assistant Researcher at the Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa (CQE-FCUL). She earned her degree in Chemistry in 2007 and completed a Master's in Chemistry with a specialization in Chemistry, Health, and Nutrition in 2008, both from FCUL. In 2013, she obtained her PhD in Chemistry, specializing in Inorganic Chemistry, from the University of Lisbon, focusing on the development of ruthenium organometallic compounds for cancer therapy.
Following her PhD, she began a postdoctoral fellowship at the Instituto de Medicina Molecular (Faculdade de Medicina, Universidade de Lisboa) and CQE-FCUL, working on peptide-metal conjugates for targeted therapies. Her work was recognized in 2014 when she received the "Portuguese Young Chemist Award" from the Portuguese Chemical Society. In 2015, Tânia was a visitor postdoc researcher at Barcelona Biomedical Research Park (PRBB), Barcelona, Spain under a Marie Sklodowska-Curie project, which allowed her to acquire important know-how in peptide synthesis. Tânia Morais is co-founder of a FCUL proto-company named "HATIcancer". In 2019, Tânia won a junior contract in the frame of CEEC Individual 2017 program and started an independent research at CQE-FCUL where she develops smart metal-peptide conjugates for targeted therapy, merging her know-how in organometallic chemistry with her expertise in peptide chemistry. In 2023, she was promoted to Assistant Researcher through CEEC Individual 5th edition program at CQE-FCUL.
Tânia research focuses on the design rational design, development, and study of inorganic, organometallic, organic, (bio)nanomaterial, and hybrid drug candidates, intended to be used for applications in healthcare. Aimed particularly at therapy and theranostics of metastatic cancers, these efforts prioritize the discovery of molecules with novel mechanisms of action, improved therapeutic efficacy, and reduced side effects.
2024 American Chemical Society Peer Reviewer Recognition
2024 Distinguished as a Royal Society of Chemistry’s 2023 outstanding reviewer
2024 Best Poster Communication
Inorganic & Bioinorganic Chemistry Conference 2024 (2024IBiCC).
2024 Best Flash Communication
4th Chem & Biochem meeting, Lisbon, Portugal
2024 Honorable Mention for Oral Communication
CQE Days 2024, Lisbon, Portugal
2022 Individual Support to Scientific Employment Stimulus
3rd Edition, Fundação para a Ciência e a Tecnologia (FCT)
2022 Best Oral Communication
CQE Days 2022, Lisbon, Portugal
2017 Individual Support to Scientific Employment Stimulus
1st Edition, Fundação para a Ciência e a Tecnologia (FCT)
2015 1st prize - ScienceIN2Business Initiative
TecLabs for Translational Research.
2014 Portuguese Young Chemist Award 2014
Award for the best doctoral thesis in chemistry (PYC-Gradiva/SPQ)
2014 Postdoctoral Fellowship
Fundação para a Ciência e a Tecnologia (FCT)
2013 Best Poster Communication
Drug Discovery & Therapy World Congress, Boston
2009 PhD Studentship
Fundação para a Ciência e a Tecnologia (FCT)